Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma
Guangyi Jiang, Liang Shi, Xueyong Zheng, Xinjie Zhang, Ke Wu, Boqiang Liu, Peijian Yan, Xiao Liang, Tunan Yu, Yifan Wang, Xiujun Cai
Abstract
. We then verified the AR/PD-L1 correlation in patients. In animal experiment we found that lower AR expressed tumor achieved better response to PD-L1 inhibitor. Thus, AR suppressed PD-L1 expression, possibly contributing to gender disparity in HCC. Better understanding of the roles of AR during HCC initiation and progression will provide a novel angle to develop potential HCC immunotherapies.
Topics & Concepts
Hepatocellular carcinomaAndrogen receptorCancer researchImmune systemImmune checkpointMedicineOncologyReceptorCarcinomaInternal medicineImmunotherapyImmunologyCancerProstate cancerCancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and PrognosisImmunotherapy and Immune Responses